Evidence map›Paper›PMID 31920383›Full record

ReviewCancer management and research2019

T-Regulatory Cells In Tumor Progression And Therapy.

Amit Verma, Rohit Mathur, Abdullah Farooque, Vandana Kaul, Seema Gupta, Bilikere S Dwarakanath

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.International journal of molecular sciences · 2020
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Immune Profiling of Meningiomas.Advances in experimental medicine and biology · 2023
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Amit VermaArmed Forces Radiobiology Research Institute, Uniformed Services University, Bethesda, MD, USA.
Rohit MathurDepartment of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abdullah FarooqueGeorgia Cancer Center, Augusta University, Georgia, GA, USA.
Vandana KaulDivision of Abdominal Transplantation, Department of Surgery, Stanford University, Stanford, CA, USA.ORCID 0000-0002-1841-5584
Seema GuptaLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.ORCID 0000-0003-0106-595X
Bilikere S DwarakanathShanghai Proton and Heavy Ion Center, Shanghai, People's Republic of China.ORCID 0000-0001-6988-2601
Augusta University Health · USGeorgetown University · USStanford University · USThe University of Texas MD Anderson Cancer Center · USUniformed Services University of the Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory T cells (Tregs) are important members of the immune system regulating the host responses to infection and neoplasms. Tregs prevent autoimmune disorders by protecting the host-cells from an immune response, related to the peripheral tolerance. However, tumor cells use Tregs as a shield to protect themselves against anti-tumor immune response. Thus, Tregs are a hurdle in achieving the complete potential of anti-cancer therapies including immunotherapy. This has prompted the development of novel adjuvant therapies that obviate their negative effects thereby enhancing the therapeutic efficacy. Our earlier studies have shown the efficacy of the glycolytic inhibitor, 2-deoxy-D-glucose (2-DG) by reducing the induced Tregs pool and enhance immune stimulation as well as local tumor control. These findings have suggested its potential for enhancing the efficacy of immunotherapy, besides radiotherapy and chemotherapy. This review provides a brief account of the current status of Tregs as a component of the immune-biology of tumors and various preclinical and clinical strategies pursued to obviate the limitations imposed by them in achieving therapeutic efficacy.

Indexed as

2-deoxy-D-glucosecyclophosphamidedendritic cellsimmune enhancementmetabolic inhibitortargeted cancer therapyT-regulatory cells

Identifiers

PMID31920383
PMCPMC6935360
OpenAlexW2994886667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.